NYSEARCA:PFNX - NYSE Arca -
12.75
-0.01 (-0.08%)
The current stock price of PFNX is 12.75 null. In the past month the price increased by 1.03%. In the past year, price increased by 70.91%.
Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf'nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California.
Pfenex Inc
10790 ROSELLE STREET
SAN DIEGO CA 92121
CEO: Evert B. Schimmelpennink
Phone: 858-352-4400
The current stock price of PFNX is 12.75 null. The price decreased by -0.08% in the last trading session.
The exchange symbol of Pfenex Inc is PFNX and it is listed on the NYSE Arca exchange.
PFNX stock is listed on the NYSE Arca exchange.
Pfenex Inc (PFNX) has a market capitalization of 437.29M null. This makes PFNX a Small Cap stock.
Pfenex Inc (PFNX) has a support level at 12.74 and a resistance level at 12.89. Check the full technical report for a detailed analysis of PFNX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PFNX does not pay a dividend.
Pfenex Inc (PFNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
ChartMill assigns a technical rating of 9 / 10 to PFNX. When comparing the yearly performance of all stocks, PFNX is one of the better performing stocks in the market, outperforming 93.5% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to PFNX. PFNX has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months PFNX reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 75% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -14.1% | ||
ROA | -6.76% | ||
ROE | N/A | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 68% to PFNX. The Buy consensus is the average rating of analysts ratings from 5 analysts.